Finland· FI-REL-REL53781
Blincyto
A blinatumomab product containing blinatumomab, registered in Finland by Orifarm Oy. The same ATC class is registered in 10 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Blinatumomab is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FX07 (blinatumomab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Blinatumomab · ATC L01FX07
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of blinatumomab costs, country by country.
Normalised to the WHO defined daily dose (18.7 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Blinatumomab · price per daily dose (18.7 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$1422.57
The record
At a glance
Fimea (Finland)- Active substance
- Blinatumomab
- Manufacturer
- Orifarm Oy
- Country
- Finland (FI)
- ATC code
- L01FX07
- ATC class
- Blinatumomab
- Defined daily dose
- 18.7 mcg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- fi_myyntilupa39216038.5 mikrog + 10 mlEUR 3014.7
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
139 interactions on record for blinatumomab.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Blinatumomab · interactions on record
139 records
- 37 severe
- 102 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Blinatumomab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayBlincytoAmgen Europe B.V.
- United KingdomBlincyto 38.5micrograms powder for concentrate and solution for solution for infusion vialsAmgen Ltd
- IrelandBLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusionAmgen Europe B.V.,
- PolandBlincytoAmgen Europe B.V.
- BelgiumBlincyto 38.5 µgAmgen Europe
- SwedenBLINCYTO 38,5 mikrogram Pulver till koncentrat och lösning till infusionsvätska, lösningAmgen Europe B.V.
- SpainBlincyto 38,5mcg de polvo para concentrado y solucion para solucion para perfusionAmgen Europe B.V.
- SwitzerlandBlincyto
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Blincyto
- Norway · Blincyto
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fb2bd318-f668-4060-ae0a-e80f93344697 GET /v1/drugs/fb2bd318-f668-4060-ae0a-e80f93344697?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "18.7",
"form": "kuiva-aine välikonsentraatiksi ja liuos infuusionestettä varten, liuos",
"route": "Laskimoon",
"ddd_unit": "mcg",
"strength": "38.5 mikrog",
"atc_label": "blinatumomabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/15/1047/001",
"fimea_rel_id": "REL53781",
"authorised_at": "2018-11-28"
}See everything about blinatumomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.